411 related articles for article (PubMed ID: 16624621)
81. [Gene therapy for primary immunodeficiency diseases].
Ariga T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():641-5. PubMed ID: 16416867
[No Abstract] [Full Text] [Related]
82. Integration of retroviral vectors.
Gabriel R; Schmidt M; von Kalle C
Curr Opin Immunol; 2012 Oct; 24(5):592-7. PubMed ID: 22981243
[TBL] [Abstract][Full Text] [Related]
83. Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector: implications for gene therapy.
Themis M; May D; Coutelle C; Newbold RF
Gene Ther; 2003 Sep; 10(19):1703-11. PubMed ID: 12923569
[TBL] [Abstract][Full Text] [Related]
84. [Safety of retroviral vectors in gene therapy].
Bogoslovskaia EV; Glazkova DV; Shipulin GA; Pokrovskiĭ VV
Vestn Ross Akad Med Nauk; 2012; (10):55-61. PubMed ID: 23240501
[TBL] [Abstract][Full Text] [Related]
85. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
86. Hematopoietic stem cell gene therapy: dead or alive?
Ferguson C; Larochelle A; Dunbar CE
Trends Biotechnol; 2005 Dec; 23(12):589-97. PubMed ID: 16216357
[TBL] [Abstract][Full Text] [Related]
87. Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase.
Southgate TD; Sheard V; Milsom MD; Ward TH; Mairs RJ; Boyd M; Fairbairn LJ
J Gene Med; 2006 May; 8(5):557-65. PubMed ID: 16506247
[TBL] [Abstract][Full Text] [Related]
88. [Development and application of gene therapy technologies].
Ozawa K
Uirusu; 2004 Jun; 54(1):49-57. PubMed ID: 15449904
[TBL] [Abstract][Full Text] [Related]
89. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia.
Kiem HP; Sellers S; Thomasson B; Morris JC; Tisdale JF; Horn PA; Hematti P; Adler R; Kuramoto K; Calmels B; Bonifacino A; Hu J; von Kalle C; Schmidt M; Sorrentino B; Nienhuis A; Blau CA; Andrews RG; Donahue RE; Dunbar CE
Mol Ther; 2004 Mar; 9(3):389-95. PubMed ID: 15006605
[TBL] [Abstract][Full Text] [Related]
90. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
[TBL] [Abstract][Full Text] [Related]
91. Micro-injection-mediated hematopoietic stem cell gene therapy.
Davis BR; Brown DB; Prokopishyn NL; Yannariello-Brown J
Curr Opin Mol Ther; 2000 Aug; 2(4):412-9. PubMed ID: 11249771
[TBL] [Abstract][Full Text] [Related]
92. Induced pluripotent stem cells and severe combined immunodeficiency: merely disease modeling or potentially a novel cure?
Mikkers H; Pike-Overzet K; Staal FJ
Pediatr Res; 2012 Apr; 71(4 Pt 2):427-32. PubMed ID: 22430378
[TBL] [Abstract][Full Text] [Related]
93. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
94. [Progress in improvement of lentiviral vectors' transcriptional read-through].
He J; Zhang J
Sheng Wu Gong Cheng Xue Bao; 2011 Nov; 27(11):1541-8. PubMed ID: 22393708
[TBL] [Abstract][Full Text] [Related]
95. Gene therapy for primary immunodeficiencies.
Fischer A; Hacein-Bey Abina S; Touzot F; Cavazzana M
Clin Genet; 2015 Dec; 88(6):507-15. PubMed ID: 25708106
[TBL] [Abstract][Full Text] [Related]
96. Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain M
Gene Ther; 2004 Apr; 11(7):569-73. PubMed ID: 15029226
[No Abstract] [Full Text] [Related]
97. Awakening gene therapy with Sleeping Beauty transposons.
Essner JJ; McIvor RS; Hackett PB
Curr Opin Pharmacol; 2005 Oct; 5(5):513-9. PubMed ID: 16084771
[TBL] [Abstract][Full Text] [Related]
98. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
99. Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.
Hammond SM; Crable SC; Anderson KP
Leuk Res; 2005 Jan; 29(1):89-97. PubMed ID: 15541480
[TBL] [Abstract][Full Text] [Related]
100. Analysis of the clonal repertoire of gene-corrected cells in gene therapy.
Paruzynski A; Glimm H; Schmidt M; Kalle Cv
Methods Enzymol; 2012; 507():59-87. PubMed ID: 22365769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
